Prof. Shune Yang 杨顺娥
Chief Physician, Professor
Department of Medical Oncology (Lymphoma), Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Standardized diagnosis and treatment of breast cancer, lymphoma, and myeloma using chemotherapy, biological targeted therapy, endocrine therapy, and autologous stem cell transplantation.
Dr. Yang graduated from Xinjiang Medical University in July 1985 and has over 30 years of experience in medical oncology. As Head of the Lymphoma and Breast Medical Departments, Dr. Yang pioneered autologous peripheral blood stem cell transplantation in Xinjiang in 1999. This work received the Third Prize for Scientific and Technological Progress in Urumqi in 2005. Dr. Yang is a doctoral supervisor and academic leader.
Professional roles
- Chair, Lymphoma Professional Committee, Xinjiang Anti-Cancer Association
- Standing Committee Member, Lymphoma Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Anti-Lymphoma Alliance, Chinese Society of Clinical Oncology (CSCO)
- Standing Committee Member, Chemotherapy Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Yang Shune). Papers usually list the name as Shune Yang or Yang S.
Selected publications
22 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Acta Biochim Biophys Sin (Shanghai), 2019 (senior author): Downregulation of MANCR inhibits cancer cell proliferation in mantle cell lymphoma possibly by interacting with RUNX2. PubMed 31650163
- Onco Targets Ther, 2018 (senior author): Expression profiles of long noncoding RNAs in lung adenocarcinoma. PubMed 30233202
- Cancer Cell Int, 2018 (senior author): MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/KLF11/Smads in hepatocellular carcinoma. PubMed 29375271
- Cancer Biomark, 2017 (senior author): Clinical potential of miRNA-221 as a novel prognostic biomarker for hepatocellular carcinoma. PubMed 27983537
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion